Sequella Receives American Recovery and Reinvestment Funding Through the NIH

Grant Funds to Finalize Synthetic Manufacturing Process for Promising New TB
Drug Candidate

ROCKVILLE, Md., Oct. 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage
biopharmaceutical company focused on commercializing novel antibiotics to
treat life-threatening infectious diseases, today announced that it received a
$694,000 grant supplement as part of the American Recovery and Reinvestment
Act (ARRA) of 2009. The ARRA funds, issued through the National Institute of
Allergy and Infectious Diseases (NIAID) of the National Institute of Health
(NIH), will assist Sequella to complete the manufacture of its lead drug
candidate, SQ109, and provide drug supplies to continue NIH grant-funded
research on SQ109 mechanism of action.

SQ109 is a new small molecule drug that is currently under US IND for the
treatment of tuberculosis and is completing its Phase I safety studies in
humans. Single, oral doses of 5 to 300 mg SQ109 were safe and well-tolerated
in normal, healthy adults in a phase 1A study. In collaboration with NIAID,
the Phase 1B clinical study to evaluate safety and pharmacokinetics of SQ109
administered daily for 2 weeks began in May 2009.

"We are pleased to receive these ARRA funds," said Dr. Carol Nacy, CEO of
Sequella. "The ARRA funds will contribute to SQ109 manufacture by
subcontractors in four different states impacted by the current economic
downturn. We are extremely appreciative of continued support from the NIH and
of the Federal Government for providing ARRA funding opportunities."

This supplemental ARRA funding will be used to complete process development
and finalize manufacture of SQ109 active pharmaceutical ingredient.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on
commercializing improved treatments for infectious diseases of epidemic
potential. The company leverages its global influence, R&D platforms, and
infectious disease expertise to proactively address emerging health threats.
Through focused execution, clear commercialization pathways, and strategic
partnerships, Sequella intends to commercialize a broad product portfolio
designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The National Institutes of Health (NIH) -- The Nation's Medical Research
Agency -- includes 27 Institutes and Centers and is a component of the U. S.
Department of Health and Human Services. It is the primary federal agency for
conducting and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments and cures for both common and rare
diseases. For more information about NIH and its programs, visit
http://www.nih.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and
supports research -- at NIH, throughout the United States, and worldwide -- to
study the causes of infectious and immune-mediated diseases and to develop
better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the
NIAID Web site at http://www.niaid.nih.gov. For comments from the NIAID
regarding this grant, please contact 301-402-1663.

SOURCE Sequella, Inc.

Alicia Moran, Brightline Media Inc., +1-703-739-2424 x 110,
Alicia@brightlinemedia.com, for Sequella, Inc.